Bristol Myers Squibb (BMY) Receivables - Other (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Receivables - Other data on file, last reported at $149.0 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $149.0 million, down 53.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.0 million (down 53.87% YoY), and the FY2025 annual result was $192.0 million, down 50.13% from the prior year.
• Receivables - Other slipped to $149.0 million in Q1 2026 per BMY's latest filing, from $192.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $1.9 billion in Q3 2023 and troughed at $149.0 million in Q1 2026.
• A 5-year average of $779.0 million and a median of $419.0 million in 2022 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 357.51% in 2025 and fell as far as 80.07% in 2025.
• A 5-year view of Receivables - Other shows it stood at $504.0 million in 2022, then dropped by 17.46% to $416.0 million in 2023, then fell by 7.45% to $385.0 million in 2024, then tumbled by 50.13% to $192.0 million in 2025, then dropped by 22.4% to $149.0 million in 2026.
• Business Quant data shows BMY's Receivables - Other at $149.0 million in Q1 2026, $192.0 million in Q4 2025, and $1.8 billion in Q3 2025.